Will COVID Vaccine Trials Reflect U.S. Diversity?
Although racial minorities, more mature individuals and those people with underlying clinical disorders are most
Although racial minorities, more mature individuals and those people with underlying clinical disorders are most at hazard from COVID-19, they’ve historically been the the very least probably to be provided in clinical trials for treatment options for severe diseases. Will that improve with COVID-19?